Every 10-Q that Relmada Therapeutics, Inc. (RLMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RLMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLMD filings page.
Relmada Therapeutics, a clinical-stage biotechnology company, has refocused its pipeline on NDV-01 for non-muscle invasive bladder cancer and sepranolone for Prader–Willi syndrome and related disorders after terminating its esmethadone and psilocybin programs in 2025.
For the quarter ended June 30, 2026, net loss was $12,914,185, contributing to a six‑month net loss of $31,966,141, driven by operating expenses of $15,011,027 in the quarter, including research and development of $8,393,789 and general and administrative expenses of $6,617,238. At June 30, 2026, cash and cash equivalents were $11,334,370 and short‑term investments were $206,396,805, supporting stockholders’ equity of $206,558,323 and an accumulated deficit of $730,233,339.
Equity raises in November 2025 and March 2026 provided net proceeds of approximately $94 million and $150 million, respectively, and management states existing cash and investments should fund operations for at least 12 months. In a Phase 2 study of NDV‑01 in high‑risk non‑muscle invasive bladder cancer, 12‑month complete responses were observed in 19/25 efficacy‑evaluable patients (76%), with no Grade ≥3 treatment‑related adverse events reported.
Relmada Therapeutics reported a Q1 2026 net loss of $19,051,956, slightly higher than the prior-year loss of $17,559,465, as it continued investing in its clinical pipeline. Research and development expense fell to $8.1 million, while general and administrative expense rose to $11.4 million.
The company strengthened its balance sheet with a March 2026 private placement that raised approximately $150 million in net proceeds, lifting cash and short-term investments to about $233.9 million and total assets to $235.4 million as of March 31, 2026. Management believes this will fund operations for at least 12 months.
Relmada’s strategy now centers on NDV-01 for non-muscle invasive bladder cancer and sepranolone for Prader-Willi syndrome and other GABA-related disorders, following termination of its esmethadone and psilocybin programs. The company plans to start Phase 3 trials for NDV-01 and a Phase 2 study for sepranolone in mid-2026.
Relmada Therapeutics (RLMD) filed its Q3 2025 10‑Q showing narrower losses and a refocused pipeline. Operating expenses fell to $10.3 million from $23.0 million a year ago, driving a net loss of $10.1 million versus $21.7 million. For the nine months, the net loss was $37.5 million, with operating cash outflow of $31.2 million. At September 30, cash was $1.38 million and short‑term investments were $12.50 million.
The company alleviated going‑concern uncertainty after closing an underwritten offering on November 5 for 40.14 million shares and 5.32 million pre‑funded warrants, generating approximately $94 million in net proceeds (before other expenses, excluding warrant exercises). Nasdaq confirmed minimum bid price compliance on September 15.
Pipeline shifted to two assets: NDV‑01 (intravesical gemcitabine/docetaxel) in Phase 2 for NMIBC showed a 92% “anytime” complete response among 25 evaluable patients and secured FDA alignment to pursue two Phase 3 studies, targeted to begin in H1 2026. Sepranolone was acquired for €3.0 million (with $2.756 million paid) and is expected to enter a Phase IIb study in Prader‑Willi Syndrome in H1 2026. Earlier esmethadone and psilocybin programs were terminated.
Relmada Therapeutics (RLMD) Q2-25 10-Q snapshot: The company remains pre-revenue and reported a Q2 net loss of $9.9 m (-44% YoY) and a 6-month loss of $27.4 m (-31% YoY) after sharply reducing R&D spend following the wind-down of its REL-1017 and psilocybin programs. Operating expenses fell 46% YoY to $10.2 m for the quarter.
Balance-sheet pressure intensified. Cash & cash equivalents dropped to $1.35 m (vs. $3.86 m YE-24) while short-term investments fell to $19.3 m (vs. $41.1 m), leaving $20.6 m of liquid resources. With $24.5 m operating cash burn in H1 and no revenue, management warns of substantial doubt about going-concern status.
Key corporate actions:
- Acquired Phase-2b-ready Sepranolone for €3 m cash.
- Licensed NDV-01 (Phase 2 NMIBC) for $3.5 m cash plus 3.0 m shares (≈10% dilution) and up to $200 m milestones; early Phase 2 data show 90% 6-month CR.
- Terminated esmethadone and psilocybin programs to focus resources on the new assets.
- Received Nasdaq bid-price deficiency notice; listing transferred to Nasdaq Capital Market with cure period to 19 Jan 2026.
Capital structure: Shares outstanding rose to 33.2 m (vs. 30.2 m YE-24); options outstanding 14.2 m; warrants 0.75 m. No ATM sales to date. Equity now stands at $15.9 m (vs. $35.5 m).
Outlook: Management is evaluating financing alternatives and may scale trial activity; upcoming catalysts include 9- and 12-month NDV-01 Phase 2 read-outs (2H-25) and planned IND for US trials in 1H-26.